Increased incidence of co-trimoxazole induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors.

Our cross-sectional study demonstrates that there is a high rate of co-trimoxazole induced drug rash, in patients treated for immune related adverse events, with those developing rash appearing to have a reduced survival.